News | May 05, 2025
Biocon Biologics secures strong market coverage for Yesintek in US
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The FDA issued Form 483 with one observation related to building and facility management
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Investment demonstrates confidence in America’s commitment to science and innovation
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Subscribe To Our Newsletter & Stay Updated
